Meeting
2022 ASCO Annual Meeting
ADVL1514, a phase 1 study of ABI-009 (nab-sirolimus) in pediatric patients with recurrent or refractory solid tumors, including CNS tumors as a single agent and in combination with temozolomide and irinotecan: A Children’s Oncology Group pediatric early-phase clinical trial network study.
Authors
Stuart Cramer
Prisma Health Children’s Hospital- Midlands, Columbia, SC
Stuart Cramer , Elizabeth Ann Gilger , Susan Burlingame , Olga Militano , Xiaowei Liu , Charles G. Minard , Alyssa Terry Reddy , Stephan D. Voss , Stacey L. Berg , Joel M. Reid , Elizabeth Fox , Brenda Weigel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT02975882
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10022)
DOI
10.1200/JCO.2022.40.16_suppl.10022
Abstract #
10022
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster
Poster
2012 ASCO Annual Meeting
Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study.
First Author: Rochelle Bagatell
Poster
2018 ASCO Annual Meeting
Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.
First Author: Steven G. DuBois
Poster
2018 ASCO Annual Meeting
ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
First Author: Suman Malempati